Survey of prenatal screening policies in Europe for structural malformations and chromosome anomalies, and their impact on detection and termination rates for neural tube defects and Down's syndrome.

OBJECTIVE: To 'map' the current (2004) state of prenatal screening in Europe. DESIGN: (i) Survey of country policies and (ii) analysis of data from EUROCAT (European Surveillance of Congenital Anomalies) population-based congenital anomaly registers. SETTING: Europe. POPULATION: Survey of prenatal screening policies in 18 countries and 1.13 million births in 12 countries in 2002-04. METHODS: (i) Questionnaire on national screening policies and termination of pregnancy for fetal anomaly (TOPFA) laws in 2004. (ii) Analysis of data on prenatal detection and termination for Down's syndrome and neural tube defects (NTDs) using the EUROCAT database. MAIN OUTCOME MEASURES: Existence of national prenatal screening policies, legal gestation limit for TOPFA, prenatal detection and termination rates for Down's syndrome and NTD. RESULTS: Ten of the 18 countries had a national country-wide policy for Down's syndrome screening and 14/18 for structural anomaly scanning. Sixty-eight percent of Down's syndrome cases (range 0-95%) were detected prenatally, of which 88% resulted in termination of pregnancy. Eighty-eight percent (range 25-94%) of cases of NTD were prenatally detected, of which 88% resulted in termination. Countries with a first-trimester screening policy had the highest proportion of prenatally diagnosed Down's syndrome cases. Countries with no official national Down's syndrome screening or structural anomaly scan policy had the lowest proportion of prenatally diagnosed Down's syndrome and NTD cases. Six of the 18 countries had a legal gestational age limit for TOPFA, and in two countries, termination of pregnancy was illegal at any gestation. CONCLUSIONS: There are large differences in screening policies between countries in Europe. These, as well as organisational and cultural factors, are associated with wide country variation in prenatal detection rates for Down's syndrome and NTD.

siRNA-Mediated Knock-Down of P-Glycoprotein Expression Reveals Distinct Cellular Disposition of Anticancer Tyrosine Kinases Inhibitors.

Studies on the cellular disposition of targeted anticancer tyrosine kinases inhibitors (TKIs) have mostly focused on imatinib while the functional importance of P-glycoprotein (Pgp) the gene product of MDR1 remains controversial for more recent TKIs. By using RNA interference-mediated knockdown of MDR1, we have investigated and compared the specific functional consequence of Pgp on the cellular disposition of the major clinically in use TKIs imatinib, dasatinib, nilotinib, sunitinib and sorafenib. siRNA-mediated knockdown in K562/Dox cell lines provides a unique opportunity to dissect the specific contribution of Pgp to TKIs intracellular disposition. In these conditions, abrogating specifically Pgp-mediated efflux in vitro revealed the remarkable and statistically significant cellular accumulation of imatinib (difference in cellular levels between Pgp-expressing and silenced cells, at high and low incubation concentration, respectively: 6.1 and 6.6), dasatinib (4.9 and 5.6), sunitinib (3.7 and 7.3) and sorafenib (1.2 and 1.4), confirming that these TKIs are all substrates of Pgp. By contrast, no statistically significant difference in cellular disposition of nilotinib was observed as a result of MDR1 expression silencing (differences: 1.1 and 1.5) indicating that differential expression and/or function of Pgp is unlikely to affect nilotinib cellular disposition. This study enables for the first time a direct estimation of the specific contribution of one transporter among the various efflux and influx carriers involved in the cellular trafficking of these major TKIs in vitro. Knowledge on the distinct functional consequence of Pgp expression for these various TKIs cellular distribution is necessary to better appreciate the efficacy, toxicity, and potential drug-drug interactions of TKIs with other classes of therapeutic agents, at the systemic, tissular and cellular levels.

Liquid fructose down-regulates liver insulin receptor substrate 2 and gluconeogeneic enzymes by modifying nutrient sensing factors in rats

High consumption of fructose-sweetened beverages has been linked to a high prevalence of chronic metabolic diseases. We have previously shown that a short course of fructose supplementation as a liquid solution induces glucose intolerance in female rats. In the present work, we characterized the fructose-driven changes in the liver and the molecular pathways involved. To this end, female rats were supplemented or not with liquid fructose (10%, w/v) for 7 or 14 days. Glucose and pyruvate tolerance tests were performed, and the expression of genes related to insulin signaling, gluconeogenesis and nutrient sensing pathways was evaluated. Fructose-supplemented rats showed increased plasma glucose excursions in glucose and pyruvate tolerance tests and reduced hepatic expression of several genes related to insulin signaling, including insulin receptor substrate 2 (IRS-2). However, the expression of key gluconeogenic enzymes, glucose-6-phosphatase and phosphoenolpyruvate carboxykinase, was reduced. These effects were caused by an inactivation of hepatic forkhead box O1 (FoxO1) due to an increase in its acetylation state driven by a reduced expression and activity of sirtuin 1 (SIRT1). Further contributing to FoxO1 inactivation, fructose consumption elevated liver expression of the spliced form of X-box-binding-protein-1 as a consequence of an increase in the activity of the mammalian target of rapamycin 1 and protein 38-mitogen activated protein kinase (p38-MAPK). Liquid fructose affects both insulin signaling (IRS-2 and FoxO1) and nutrient sensing pathways (p38-MAPK, mTOR and SIRT1), thus disrupting hepatic insulin signaling without increasing the expression of key gluconeogenic enzymes.

Síndrome de boca ardiente: claves diagnósticas y terapéuticas

El síndrome de boca ardiente (SBA) se conoce también como boca escaldada, ardor bucal, glosodinia, glosopirosis, estomatodinia, estomatopirosis o disestesia oral. Se caracteriza por dolor o sensación de ardor, escozor o picazón, a veces aspereza, sobre todo en la lengua, paladar duro y labio inferior, en ausencia de datos clínicos o de laboratorio que justifiquen estos síntomas. Puede acompañarse de disgeusia (trastornos del gusto) y de xerostomía (boca seca), constituyendo la tríada clásica. Su etiología, poco precisa, es multifactorial. La evolución del cuadro tiende a ser crónica, alternando períodos de exacerbación y mejoría durante meses o años. Es más frecuente en mujeres perimenopáusicas o posmenopáusicas. Los episodios de SBA aparecen de forma espontánea y presentan un abanico variable en la gravedad de los síntomas. Mientras algunos pacientes refieren malestar leve o moderado, otros manifiestan dolor insoportable. Los síntomas suelen ser menos intensos...

Síndrome de boca ardiente: claves diagnósticas y terapéuticas

El síndrome de boca ardiente (SBA) se conoce también como boca escaldada, ardor bucal, glosodinia, glosopirosis, estomatodinia, estomatopirosis o disestesia oral. Se caracteriza por dolor o sensación de ardor, escozor o picazón, a veces aspereza, sobre todo en la lengua, paladar duro y labio inferior, en ausencia de datos clínicos o de laboratorio que justifiquen estos síntomas. Puede acompañarse de disgeusia (trastornos del gusto) y de xerostomía (boca seca), constituyendo la tríada clásica. Su etiología, poco precisa, es multifactorial. La evolución del cuadro tiende a ser crónica, alternando períodos de exacerbación y mejoría durante meses o años. Es más frecuente en mujeres perimenopáusicas o posmenopáusicas. Los episodios de SBA aparecen de forma espontánea y presentan un abanico variable en la gravedad de los síntomas. Mientras algunos pacientes refieren malestar leve o moderado, otros manifiestan dolor insoportable. Los síntomas suelen ser menos intensos...

Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance.

Down syndrome (DS) is characterized by extensive phenotypic variability, with most traits occurring in only a fraction of affected individuals. Substantial gene-expression variation is present among unaffected individuals, and this variation has a strong genetic component. Since DS is caused by genomic-dosage imbalance, we hypothesize that gene-expression variation of human chromosome 21 (HSA21) genes in individuals with DS has an impact on the phenotypic variability among affected individuals. We studied gene-expression variation in 14 lymphoblastoid and 17 fibroblast cell lines from individuals with DS and an equal number of controls. Gene expression was assayed using quantitative real-time polymerase chain reaction on 100 and 106 HSA21 genes and 23 and 26 non-HSA21 genes in lymphoblastoid and fibroblast cell lines, respectively. Surprisingly, only 39% and 62% of HSA21 genes in lymphoblastoid and fibroblast cells, respectively, showed a statistically significant difference between DS and normal samples, although the average up-regulation of HSA21 genes was close to the expected 1.5-fold in both cell types. Gene-expression variation in DS and normal samples was evaluated using the Kolmogorov-Smirnov test. According to the degree of overlap in expression levels, we classified all genes into 3 groups: (A) nonoverlapping, (B) partially overlapping, and (C) extensively overlapping expression distributions between normal and DS samples. We hypothesize that, in each cell type, group A genes are the most dosage sensitive and are most likely involved in the constant DS traits, group B genes might be involved in variable DS traits, and group C genes are not dosage sensitive and are least likely to participate in DS pathological phenotypes. This study provides the first extensive data set on HSA21 gene-expression variation in DS and underscores its role in modulating the outcome of gene-dosage imbalance.

Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid.

OBJECTIVE: We developed interferon-α-kinoid (IFN-K), a drug composed of inactivated IFNα coupled to a carrier protein, keyhole limpet hemocyanin. In human IFNα-transgenic mice, IFN-K induces polyclonal antibodies that neutralize all 13 subtypes of human IFNα. We also previously demonstrated that IFN-K slows disease progression in a mouse model of systemic lupus erythematosus (SLE). This study was undertaken to examine the safety, immunogenicity, and biologic effects of active immunization with IFN-K in patients with SLE. METHODS: We performed a randomized, double-blind, placebo-controlled, phase I/II dose-escalation study comparing 3 or 4 doses of 30 μg, 60 μg, 120 μg, or 240 μg of IFN-K or placebo in 28 women with mild to moderate SLE. RESULTS: IFN-K was well tolerated. Two SLE flares were reported as serious adverse events, one in the placebo group and the other in a patient who concomitantly stopped corticosteroids 2 days after the first IFN-K dose, due to mild fever not related to infection. Transcriptome analysis was used to separate patients at baseline into IFN signature-positive and -negative groups, based on the spontaneous expression of IFN-induced genes. IFN-K induced anti-IFNα antibodies in all immunized patients. Notably, significantly higher anti-IFNα titers were found in signature-positive patients than in signature-negative patients. In IFN signature-positive patients, IFN-K significantly reduced the expression of IFN-induced genes. The decrease in IFN score correlated with the anti-IFNα antibody titer. Serum complement C3 levels were significantly increased in patients with high anti-IFNα antibody titers. CONCLUSION: These results show that IFN-K is well tolerated, immunogenic, and significantly improves disease biomarkers in SLE patients, indicating that further studies of its clinical efficacy are warranted.

The complex SNP and CNV genetic architecture of the increased risk of congenital heart defects in Down syndrome.

Congenital heart defect (CHD) occurs in 40% of Down syndrome (DS) cases. While carrying three copies of chromosome 21 increases the risk for CHD, trisomy 21 itself is not sufficient to cause CHD. Thus, additional genetic variation and/or environmental factors could contribute to the CHD risk. Here we report genomic variations that in concert with trisomy 21, determine the risk for CHD in DS. This case-control GWAS includes 187 DS with CHD (AVSD = 69, ASD = 53, VSD = 65) as cases, and 151 DS without CHD as controls. Chromosome 21-specific association studies revealed rs2832616 and rs1943950 as CHD risk alleles (adjusted genotypic P-values <0.05). These signals were confirmed in a replication cohort of 92 DS-CHD cases and 80 DS-without CHD (nominal P-value 0.0022). Furthermore, CNV analyses using a customized chromosome 21 aCGH of 135K probes in 55 DS-AVSD and 53 DS-without CHD revealed three CNV regions associated with AVSD risk (FDR ≤ 0.05). Two of these regions that are located within the previously identified CHD region on chromosome 21 were further confirmed in a replication study of 49 DS-AVSD and 45 DS- without CHD (FDR ≤ 0.05). One of these CNVs maps near the RIPK4 gene, and the second includes the ZBTB21 (previously ZNF295) gene, highlighting the potential role of these genes in the pathogenesis of CHD in DS. We propose that the genetic architecture of the CHD risk of DS is complex and includes trisomy 21, and SNP and CNV variations in chromosome 21. In addition, a yet-unidentified genetic variation in the rest of the genome may contribute to this complex genetic architecture.

Síndrome de quemarse en el trabajo (Burnout) y estrategias de afrontamiento: un modelo de relaciones estructurales

En este estudio se examina un modelo de relaciones estructurales entre las dimensiones del síndrome de quemarse en el trabajo, y estrategias de afrontamiento orientadas al control y a la ausencia de control sobre los estresores laborales y las emociones individuales. Se plantea la hipótesis de que si la realización personal y el agotamiento emocional se dan de un modo simultáneo, la realización personal tendrá un mayor impacto sobre el cansancio emocional. Los resultados obtenidos se discuten con relación al uso de modelos no recursivos, los efectos de la controlabilidad que implican distintas estrategias de afrontamiento sobre las dimensiones del síndrome de quemarse, e implicaciones para la prevención del estrés en el trabajo.

Neuropsicología de los pacientes con síndrome de fibromialgia: relación con dolor y ansiedad

Estudios previos han mostrado la presencia de alteraciones cognitivas en los pacientes con síndrome de fibromialgia (SFM), sin embargo, no han determinado la posible influencia de las distintas variables clínicas en estas alteraciones. El primer objetivo de nuestro estudio es determinar las diferencias en la función cognitiva entre 81 pacientes con SFM y 35 controles sanos mediante una batería de tests neuropsicológicos. El segundo objetivo es determinar la influencia de la ansiedad y el dolor en la función cognitiva en pacientes con SFM. Los resultados de nuestro estudio muestran que las pacientes con SFM desarrollan un rendimiento cognitivo significativamente inferior a los controles sanos en todos los parámetros valorados. El rendimiento neuropsicológico en pacientes con SFM está asociado al dolor, siendo esta relación independiente del nivel de ansiedad. La relación entre el rendimiento cognitivo y la ansiedad también es significativa. Por esta razón, concluimos que el rendimiento cognitivo está principalmente afectado por el dolor, pero además, el nivel de ansiedad explica parte de la variabilidad en los tests neuropsicológicos que no es explicada por el dolor.

Avances en el estudio del "torrao" o cribado del tomate

El "torrao" es una enfermedad presente en nuestro país desde 2001, que sigue presentándose en cada campaña de tomate con mayor o menor incidencia según el año. Las plantas afectadas muestran necrosis en la parte basal de los foliolos que puede evolucionar a cribado, manchas longitudinales en los peciolos y manchas necróticas en fruto, que terminan por rajarlo. El presente trabajo es la continuación del publicado en el número 32 de esta revista titulado "Necrosis del tomate: "torrao" o cribado" y surge de los resultados obtenidos tras la reciente publicación de la identificación y caracterización del nuevo virus "Tomato torrado virus" (ToTV) como agente implicado en la enfermedad conocida como "torrao". En este estudio se seleccionaron 94 muestras procedentes de prospecciones realizadas en invernaderos de Murcia durante los años 2003 a 2006. La aplicación RT-PCR e hibridación molecular para la detección de ToTV ha permitido detectar la presencia de esta nueva virosis en 87 de las muestras analizadas. En 83 de ellas, se encontró la presencia conjunta de este nuevo virus con el Pepino mosaic virus (PepMV), mayoritariamente con el aislado tipo Chileno 2 (Accesión number: DQ00095). Se plantean nuevos estudios para determinar la implicación de ambos virus, ToTV y PepMV, en el desarrollo del síndrome conocido como "torrao" del tomate.

Necrosis del tomate: "torrao "o "cribado"

Desde la primavera de 2001, viene presentándose en España una nueva enfermedad conocida con el nombre de "torrao" o "cribado". Los síntomas que habitualmente presentan las plantas afectadas son una necrosis en la parte basal del foliolo que evoluciona a cribado, en los peciolos aparecen manchas longitudinales en ocasiones endurecidas que llegan a curvar los foliolos, y los frutos manifiestan manchas necróticas, deformaciones que finalmente lo rajan, quedando comercialmente inviables. Muestreos realizados desde su aparición han determinado la mayor incidencia de la enfermedad en la zona de Murcia, seguido de Canarias y en menor proporción Almería, y Alicante. Los resultados de los análisis realizados a las 369 muestras recogidas determinan que el 67% de las muestras analizadas eran positivas a Pepino mosaic virus (PepMV). En los ensayos de transmisión, únicamente mediante el injerto, se consiguió reproducir los síntomas de la enfermedad en dos casos, en el resto las plantas inoculadas e injertadas únicamente mostraban síntomas típicos de PepMV y los análisis realizados confirmaron este aspecto. A la vista de los resultados obtenidos, se diseñó un nuevo método de diagnóstico que ha permitido la caracterización del 89% de las muestras analizadas como aislado Chileno 2 de PepMV, recientemente publicado en el Gen Bank (Accesión number: DQ000985). De acuerdo con lo expuesto podría tratarse de uno de los agentes implicados en el desarrollo del síndrome junto con otros factores aún por determinar